Trial Profile
A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab-deruxtecan (Primary) ; Irinotecan; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms DESTINY-Gastric01
- Sponsors Daiichi Sankyo Company
- 21 Jan 2023 Results investigating use of computational pathology based tools enables precise and accurate quantification of HER2 expression and spatial analysis, which enables design of better scores to reflect the T DXd mechanism of action, by deriving data from NCT03329690 and NCT04014075, presented at the 2023 Gastrointestinal Cancers Symposium
- 19 Dec 2022 According to an AstraZeneca media release, based on results from the DESTINY-Gastric02 and DESTINY-Gastric01 trials, ENHERTU has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
- 19 Dec 2022 According to a Daiichi Sankyo Company media release, based on results from the DESTINY-Gastric02 and DESTINY-Gastric01 trials, ENHERTU has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.